{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:16:36Z","timestamp":1791141396380,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Comput Assist Tomogr"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>The aim of this study was to assess the role of dynamic contrast-enhanced perfusion computed tomography (pCT) imaging in the early detection of blood flow changes related to antiangiogenic treatment with sorafenib, in patients with advanced hepatocellular carcinoma (HCC), being the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria the standard of reference.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between 2012 and 2016, 43 cirrhotic patients (male, n = 39; female, n = 4) with biopsy-proven multifocal HCC underwent multi\u2013detector-row computed tomography, and pCT examinations were performed before and every 2 months after sorafenib administration. Perfusion CT technique is based on the acquisition of 16 dynamic slices\/scan per 40 scans, performed on a 256-slice multi\u2013detector-row computed tomography scanner, after intravenous bolus injection of 50 mL of iodinated contrast agent (350 mg I\/mL) at a flow rate of 5 mL\/s. According to mRECIST, patients were stratified into complete (CR) or partial response (PR) and stable (SD) or progressive disease (PD). The following pCT parameters were calculated: hepatic perfusion (mL\/s per 100 g), time to peak (seconds), arterial perfusion (mL\/s), and hepatic perfusion index (%). Perfusion CT values at baseline and first follow-up were reported for all mRECIST groups and then compared between the nonprogressor (CR, PR, SD) and progressor groups (PD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Most pCT values were significantly higher (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01) between baseline and follow-up in the CR and PR groups, whereas nonsignificant differences were found among SD patients, and a nonsignificant  trend (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05) toward increase was observed among PD patients. Moreover, pCT values were significantly higher (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.05) at baseline in the nonprogressor group compared with the progressor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Preliminary results suggest that pCT adds quantitative data of vascularization, thus demonstrating its usefulness in the assessment of therapeutic response to sorafenib in advanced HCC, in line with mRECIST criteria, offering 1-step information on tissue cellularity and vascularization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rct.0000000000000807","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T18:36:47Z","timestamp":1541615807000},"page":"206-213","source":"Crossref","is-referenced-by-count":9,"title":["Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Davide","family":"Ippolito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pecorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cammillo","family":"Talei Franzesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Okolicsanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Strazzabosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230927","first-page":"153","article-title":"Current management of hepatocellular carcinoma","volume":"10","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"bib2-20230927","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"bib3-20230927","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib4-20230927","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/jcp.2003.015784","article-title":"Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma","volume":"57","year":"2004","journal-title":"J Clin Pathol"},{"key":"bib5-20230927","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"bib6-20230927","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ctrv.2008.12.001","article-title":"Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy","volume":"35","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"bib7-20230927","first-page":"25","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","year":"2010","journal-title":"Lancet Oncol"},{"key":"bib8-20230927","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2012.08.022","article-title":"Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"bib9-20230927","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona\u20132000 EASL conference. European Association for the Study of the Liver","volume":"35","year":"2001","journal-title":"J Hepatol"},{"key":"bib10-20230927","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib11-20230927","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","year":"2010","journal-title":"Semin Liver Dis"},{"key":"bib12-20230927","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1007\/s00535-014-0936-0","article-title":"Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma","volume":"49","year":"2014","journal-title":"J Gastroenterol"},{"key":"bib13-20230927","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1148\/radiol.11110282","article-title":"Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models","volume":"262","year":"2012","journal-title":"Radiology"},{"key":"bib14-20230927","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2013.01.039","article-title":"Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"bib15-20230927","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000358599","article-title":"Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?","volume":"86","year":"2014","journal-title":"Oncology"},{"key":"bib16-20230927","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.ejrad.2012.12.004","article-title":"Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results","volume":"82","year":"2013","journal-title":"Eur J Radiol"},{"key":"bib17-20230927","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLI.0b013e3182199bb5","article-title":"Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST)","volume":"47","year":"2012","journal-title":"Invest Radiol"},{"key":"bib18-20230927","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1148\/radiol.2433052020","article-title":"Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience","volume":"243","year":"2007","journal-title":"Radiology"},{"key":"bib19-20230927","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1148\/radiol.10091870","article-title":"Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification\u2014preliminary results","volume":"258","year":"2011","journal-title":"Radiology"},{"key":"bib20-20230927","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2007.13.8156","article-title":"Reflections on medical oncology: 25 years of clinical trials\u2014where have we come and where are we going?","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib21-20230927","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"bib22-20230927","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.ejrad.2015.02.020","article-title":"Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique","volume":"84","year":"2015","journal-title":"Eur J Radiol"},{"key":"bib23-20230927","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11547-013-0332-5","article-title":"Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib. Preliminary results","volume":"119","year":"2014","journal-title":"Radiol Med"},{"key":"bib24-20230927","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12013-014-9877-8","article-title":"Application of 128 slice 4D CT whole liver perfusion imaging in hepatic tumor","volume":"70","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"bib25-20230927","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.dld.2013.03.004","article-title":"Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study","volume":"45","year":"2013","journal-title":"Dig Liver Dis"},{"key":"bib26-20230927","doi-asserted-by":"crossref","first-page":"20130695","DOI":"10.1259\/bjr.20130695","article-title":"Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study","volume":"87","year":"2014","journal-title":"Br J Radiol"},{"key":"bib27-20230927","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1148\/radiol.2017174012","article-title":"Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy","volume":"283","year":"2017","journal-title":"Radiology"},{"key":"bib28-20230927","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/0284185117732805","article-title":"Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up","volume":"59","year":"2018","journal-title":"Acta Radiol"},{"key":"bib29-20230927","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2017.10.017","article-title":"Hepatocellular carcinoma treated with sorafenib: arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival","volume":"98","year":"2018","journal-title":"Eur J Radiol"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004728-201903000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T18:18:05Z","timestamp":1695838685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004728-201903000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000000807","relation":{},"ISSN":["1532-3145","0363-8715"],"issn-type":[{"value":"1532-3145","type":"electronic"},{"value":"0363-8715","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}